Mupirocin

Mupirocin

• CAS Number: 12650-69-0
• UNSPSC Description: Mupirocin (BRL-4910A, Pseudomonic acid) is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[1][2].
• Target Antigen: Antibiotic; Bacterial
• Type: Natural Products
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/Mupirocin.html
• Purity: 98.34
• Solubility: DMSO : ≥ 100 mg/mL
• Smiles: O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O)=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2
• Molecular Weight: 500.62
• References & Citations: [1]Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8.|[2]Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70.|[3]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42(3):272-5.|[4]Mohammad H, Abutaleb NS, Dieterly AM, Lyle LT, Seleem MN. Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs. Sci Rep. 2021 May 25;11(1):10935.|[5]Giacometti A, et al. Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. Antimicrob Agents Chemother. 2000 Oct. 44(10):2842-4.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched